

Supplemental Table 2. Repartition of vasodilators, aspirin and vitamine K antagonists intake among patients with positivity for ≥ 1 aPL

Treatments	≥ 1 aPL (n=31)
Calcium channel inhibitors, n (%)	23 (74) ^a
Endothelin receptor agonist (bosentan), n (%)	7 (23) ^b
Low dose aspirin, n (%)	20 (65) ^c
Vitamin K antagonists, n (%)	6 (19) ^d

^a Twelve patients with ADU (all received calcium channel inhibitors) and 11 without ADU

^b All had ADU (six with Raynaud's severity score of 3 and one with a score of 4)

^c Include the 7 patients with APS. Regarding only patients positive for ≥ 1 aPL without APS (n=24), all the 9 patients with ADU received aspirin vs 9/15 without ADU (60%)

^d Correspond to 6 patients with definite APS (total APS=7, one received unfractionned heparin at the inclusion in the study)

aPL: antiphospholipid antibodies, APS: antiphospholipid syndrome; ADU: active digital ulceration